Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 258Carcinoma, Non-Small-Cell Lung 226Carcinoma, Renal Cell 143Neoplasm Metastasis 97Neoplasms 93Carcinoma, Hepatocellular 85Squamous Cell Carcinoma of Head and Neck 84Colorectal Neoplasms 81Lung Neoplasms 73Stomach Neoplasms 56Pancreatic Neoplasms 56Carcinoma, Transitional Cell 49Hodgkin Disease 47Urinary Bladder Neoplasms 42Breast Neoplasms 40Ovarian Neoplasms 37Head and Neck Neoplasms 37Triple Negative Breast Neoplasms 34Small Cell Lung Carcinoma 33Sarcoma 32Prostatic Neoplasms 32Glioblastoma 32Brain Neoplasms 32Recurrence 27Kidney Neoplasms 27Multiple Myeloma 25Uveal Melanoma 23Esophageal Neoplasms 23Uterine Cervical Neoplasms 22Skin Neoplasms 22

Interventions

Paracentesis 2Bevacizumab 2regramostim 1recombinant human tumor necrosis factor-binding protein-1 1pembrolizumab 1molgramostim 1irinotecan sucrosofate 1Nivolumab 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Malignant Ascites × Nivolumab × Clear all
NCT05745233 2023-08-24

Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites

China Medical University Hospital

Phase NA Enrolling by invitation
30 enrolled

Malignant Ascites

Data powered by HemOnc (CC BY 4.0) Colophon âš¡